# TaxXel: Taxotere and Xeloda in Esophageal Cancer

> **NCT00821912** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Karolinska University Hospital** · enrollment: 93 (actual)

## Conditions studied

- Cancer of the Esophagus
- Gastric Cardia Carcinoma

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00821912
- **Lead sponsor:** Karolinska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-03
- **Primary completion:** 2012-09
- **Final completion:** 2013-09
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2012-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00821912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00821912, "TaxXel: Taxotere and Xeloda in Esophageal Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00821912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*